Regeneron expands clinical-stage obesity portfolio with strategic in-licensing of novel dual glp-1/gip receptor agonist

New licensing agreement with hansoh pharma provides regeneron with hs-20094, a glp-1/gip receptor agonist in advanced stages of clinical development in china

REGN Ratings Summary

REGN Quant Ranking